BRAF and skin squamous cell carcinoma: Acquired resistance and development of secondary squamous cell skin cancers and other skin toxicities associated with BRAF inhibitors caused by the paradoxical activation of wild-type BRAF kinase in the MAPK pathway in normal tissues were the challenges faced with BRAF inhibitor monotherapy.